Updates are available Correction dated 2019-05-23

Article History

Received: 13 December 2018

Accepted: 27 December 2018

First Online: 16 January 2019

Change Date: 23 May 2019

Change Type: Correction

Change Details: AbstractFollowing publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442–1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All changes are marked in bold and with red in Figure 1 and Figure 2. Please note that the final recommendations remain unchanged.

Ethics approval and consent to participate

: Ethics approval and consent to participate was not needed for this consensus.

: All authors have reviewed the final version and gave their approval for publication.

: Authors, Financial disclosure (consulting, speaking fees, travel grants, research support). Simona Sacco Allergan, Bayer Healthcare, Eli Lilly, Medtronic, Novartis, TEVA. Lars Bendtsen Allergan, Biogen, Novartis, Teva. Messoud Ashina Allergan, Alder, Amgen, Eli Lilly, Novartis, Teva. Dimos-Dimitrios Mitsikostas Allergan, Amgen, Cefaly, ElectroCore, Genesis Pharma, Eli Lilly, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Speficar, Teva. Uwe Reuter Amgen, Autonomic Technologies Eli Lilly, Novartis, Teva. Gisela Terwindt Eli Lilly, Novartis, Teva. Paolo Martelletti Allergan, Amgen, Electrocore, Eli Lilly, Novartis, Springer HealthCare, Teva.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.